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ABSTRACT
Objectives Randomised controlled trials conducted using 
cohorts and routinely collected data, including registries, 
electronic health records and administrative databases, 
are increasingly used in healthcare intervention research. 
A Consolidated Standards of Reporting Trials (CONSORT) 
statement extension for trials conducted using cohorts and 
routinely collected data (CONSORT- ROUTINE) has been 
developed with the goal of improving reporting quality. 
This article describes the processes and methods used to 
develop the extension and decisions made to arrive at the 
final checklist.
Methods The development process involved five 
stages: (1) identification of the need for a reporting 
guideline and project launch; (2) conduct of a 
scoping review to identify possible modifications to 
CONSORT 2010 checklist items and possible new 
extension items; (3) a three- round modified Delphi 
study involving key stakeholders to gather feedback 
on the checklist; (4) a consensus meeting to finalise 
items to be included in the extension, followed 
by stakeholder piloting of the checklist; and (5) 
publication, dissemination and implementation of the 
final checklist.
Results 27 items were initially developed and rated 
in Delphi round 1, 13 items were rated in round 2 and 
11 items were rated in round 3. Response rates for the 
Delphi study were 92 of 125 (74%) invited participants 
in round 1, 77 of 92 (84%) round 1 completers in 
round 2 and 62 of 77 (81%) round 2 completers in 
round 3. Twenty- seven members of the project team 
representing a variety of stakeholder groups attended 
the in- person consensus meeting. The final checklist 
includes five new items and eight modified items. The 
extension Explanation & Elaboration document further 
clarifies aspects that are important to report.
Conclusion Uptake of CONSORT- ROUTINE and accompanying 
Explanation & Elaboration document will improve conduct 
Strengths and limitations of this study
 ► We followed a five- step process to develop 
Consolidated Standards of Reporting Trials state-
ment extension for trials conducted using cohorts 
and routinely collected data (CONSORT- ROUTINE), 
consistent with Enhancing the QUAlity and 
Transparency Of health Research guidance.
 ► Items were informed by reporting guidelines on sim-
ilar research designs, a scoping review, a three- round 
Delphi process and expert members of the guideline 
development team.
 ► CONSORT- ROUTINE was reviewed and tested at 
various stages of the development by project team 
members and key stakeholders.
 ► The limited methodological literature on trials con-
ducted using cohorts and routinely collected data 
was a limitation in developing the extension.
 ► Similar to other reporting guidelines, CONSORT- 
ROUTINE will require re- evaluation and revisions 
over time to ensure that it is kept up to date with 
evolving methodology and practice of trials using 
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of trials, as well as the transparency and completeness of reporting of trials 
conducted using cohorts and routinely collected data.
BACKGROUND
The use of reporting guidelines, including the Consol-
idated Standards of Reporting Trials (CONSORT) 
statement, improves the transparency and complete-
ness of reports of results from randomised controlled 
trials (RCTs).1–4 The CONSORT statement helps to 
facilitate critical appraisal and interpretation of RCTs 
by providing guidance to authors on a minimal set 
of items that should be reported for all trials.5 The 
CONSORT 2010 guideline aimed to improve the 
reporting of two- arm parallel group RCTs. Extensions 
of the CONSORT statement have been developed 
to encourage better reporting of other trial designs, 
including, for instance, multiarm parallel group 
randomised trials, cluster trials, pilot and feasibility 
trials and pragmatic trials.6–9
There is a growing interest in RCTs conducted using 
cohorts or routinely collected data, including regis-
tries, electronic health records (EHRs) and administra-
tive databases.10–14 In a cohort, a group of individuals 
is gathered for the purpose of conducting research, 
whereas routinely collected data refer to data initially 
collected for purposes other than research or without 
specific a priori research questions developed before 
collection.15 16 Trials may use a cohort or routinely 
collected data for: (1) identification of eligible partic-
ipants, (2) outcome ascertainment and (3) to imple-
ment an intervention, or for a combination of these 
purposes. For example, in registry- based RCTs, a 
registry could be used to identify eligible participants 
for a trial, for the collection of participant baseline 
characteristics and as the source of outcome data; 
some registries have used interactive technology to 
actively flag participants for RCT enrolment as patient 
data are entered into the registry.12 In some EHR 
trials, the EHR itself is used to implement an interven-
tion. For example, one RCT tested an intervention to 
reduce antibiotic prescribing by feeding back person-
alised antibiotic prescription data to primary care 
physicians.17
The use of cohorts and routinely collected data may 
make RCTs easier and more feasible to perform by 
reducing cost, time and other resources.18 19 It may 
also facilitate the conduct of trials that more closely 
replicate real- world clinical practice. These trial 
designs, however, are relatively recent innovations, and 
published RCT reports may not describe important 
aspects of their methodology in a standardised way. 
Trials conducted using cohorts and routinely collected 
data share certain elements with conventional RCTs, 
but there are also distinctive elements to report that 
are not covered in the CONSORT 2010 statement. 
The REporting of studies Conducted using Observa-
tional Routinely- collected Data (RECORD) statement 
provides guidance on reporting of studies conducted 
using routinely collected data but does not address 
RCT- specific methodological and reporting consider-
ations.20 Research conducted using routinely collected 
data presents unique methodological challenges that 
are often insufficiently reported, but there is scant 
guidance on methods and reporting of trials conducted 
using routinely collected data or cohorts.21 22
An extension to the CONSORT statement for RCTs 
conducted using cohorts and routinely collected 
data was developed using methods recommended 
for developing reporting guidelines.23 This article 
describes, in detail, the consensus- based develop-
ment process. The main aims of this article are to: 
(1) describe the methods and processes used in the 
development of the CONSORT Extension for Trials 
Conducted Using Cohorts and Routinely Collected 
Data (CONSORT-ROUTINE; Kwakkenbos et al)24 
and (2) describe decisions made to arrive at the final 
checklist and the accompanying Explanation & Elabo-
ration statement.
METHODS
The project was registered with the Enhancing 
the QUAlity and Transparency Of health Research 
(EQUATOR) network.25 We followed the EQUATOR 
network’s guidelines for recommended methods and 
processes for developing, disseminating and imple-
menting healthcare reporting guidelines.23 These 
methods have been used in the development of other 
similar EQUATOR guidelines. Figure 1 illustrates 
the five parts of the development process for this 
guideline.
Figure 1 Development process of the CONSORT Extension 
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Project phase 1: project launch, establishment of team and 
funding
Need for the guideline and literature review
An initial informal review of reports of published 
protocols and reports of trials using cohorts and 
routinely collected data by BDT and LK suggested that 
there appeared to be deficiencies in reporting of such 
trials. For instance, many reports did not adequately 
describe the cohort or database from which trial 
participants were recruited, processes used to link 
participants across databases were not always provided 
and it was sometimes unclear whether trial outcomes 
were assessed by the triallists or ascertained via existing 
databases used to conduct the trial. A review of the 
EQUATOR website and published literature indicated 
that there was no existing reporting guideline for 
these types of trials. The RECORD statement addresses 
reporting issues related to routinely collected data 
but does not include guidance on reporting of trials. 
Many trials conducted using routinely collected data 
are pragmatic or use cluster designs, for instance, 
but CONSORT extensions for those types of trials do 
not address issues germane to the use of cohorts or 
routinely collected data to conduct trials.7 9
Project launch and identification of CONSORT-ROUTINE project 
members
Initial discussions on developing a CONSORT exten-
sion for RCTs conducted using cohorts occurred in 
November 2016 at the Trials within Cohorts sympo-
sium in London, UK (LK, MZ, CR and BDT).26 Discus-
sions continued virtually and key people involved in 
cohort- embedded trials or the EQUATOR network 
were approached during December 2016 (HMV, DM, 
IB, PR, JN, RU and DT). It was suggested that trials 
conducted in registries had many characteristics 
similar to those in cohorts, and there was agreement to 
include registry- based trials in the extension. People 
with expertise in registry- based trials were approached 
in March 2017 (OF, LT, MKC and DE), and an expe-
rienced librarian (MSam) and patient representative 
familiar with trials conducted using cohorts (MSau) 
were also included in the group at that point.
The project was registered on the EQUATOR 
website in April 2017. During the preparatory phase, 
while developing searches and reviewing example 
publications, we became aware that trials conducted 
using EHRs and administrative databases also shared 
similar characteristics with trials in cohorts and regis-
tries, and it was decided to expand the scope to trials 
conducted using cohorts and routinely collected data. 
In July 2017, triallists, who were leading the develop-
ment of a reporting guideline for EHRs, joined the 
project group (EJ and CG). Given the relevance of 
their previous work and their expertise (LH, SL, DM 
and EIB), authors who had been involved in the devel-
opment of the RECORD statement were invited to 
join the team.20 Several doctoral students also joined 
the project team (SJM, KAM and DBR). A steering 
committee comprising of 10 members with key exper-
tise for consultation was established. A research coor-
dinator (MI) was hired in April 2018 to manage the 
project, and an experienced journal editor was invited 
to join (JF). The group communicated regularly 
throughout the process via a number of virtual meet-
ings, using an online platform to conduct teleconfer-
ences, as well as through email discussions.
Rationale for developing one checklist versus four different 
checklists for trials conducted using cohorts, registries, EHRs and 
administrative databases
Team members discussed the advantages and disadvan-
tages of creating individual checklists for each of the four 
types of data versus a single checklist for all four. It was 
determined that, although there are some differences in 
the implementation of trials across the different types of 
data sources, the methodological principles are similar, 
and there is substantial overlap in the design, conduct 
and factors that may influence interpretability. Thus, 
the steering committee reached consensus to develop a 
single statement, addressing any differences by including 
‘if applicable’ to items in the checklist that may not apply 
to all trial designs and to clarify differences in the Expla-
nation & Elaboration publication as deemed necessary.
Funding
The project team obtained its main source of funding 
from a grant from the Canadian Institutes of Health 
Research Institutes (CIHR) to support the development of 
the guideline (BDT, OF, EJ, LK, CR; Grant #PJT-156172). 
EJ and CG also obtained funding from the UK National 
Institute of Health Research Clinical Trials Unit Support 
Funding - Supporting efficient/innovative delivery of 
NIHR research. In addition, funding to hold the face- 
to- face meeting was provided by a Planning and Dissem-
ination Grant from CIHR (BDT and LK; Grant #PCS 
- 161863) and by contributions from Queen Mary Univer-
sity of London, the University of Sheffield, McGill Univer-
sity and the Lady Davis Institute for Medical Research of 
the Jewish General Hospital in Montreal, Canada.
A project protocol was developed and published.22
Project phase 2: scoping review
A preliminary ‘long list’ of possible reporting items 
was formulated by LK and KAM based on review of the 
CONSORT 2010 statement items, the Strengthening 
the Reporting of Observational Studies in Epidemiology 
(STROBE)27 and the RECORD statements,20 as well 
as discussions with steering committee members. The 
STROBE and RECORD statements were considered the 
most relevant to this project because of their focus on 
reporting of observational studies and non- interventional 
studies using routinely collected data.
A scoping review was conducted to identify: (1) articles 
on the methodology or reporting of RCTs conducted 
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inform the development of new items or modification of 
existing CONSORT items; and (2) trial reports to identify 
aspects of reporting that need improvement and exam-
ples of good reporting of potential checklist items that 
could be used to support CONSORT- ROUTINE.28 We 
searched for relevant articles on trials conducted using 
cohorts, registries, EHRs and administrative databases 
from 2007 to 2018. After screening articles for inclusion 
and exclusion at the abstract and full- text level, 10 people 
from the team independently reviewed the included 
papers and provided suggestions for modifications or 
additional reporting guideline items until no new ideas 
emerged (saturation). Suggestions were added in a stan-
dardised, shared spreadsheet. At the same time, team 
members provided examples of good reporting for each 
proposed item or item modification. Additionally, the 
review helped us to create a list of authors with experi-
ence in these trial designs as potential participants for the 
Delphi study. Search terms used in the scoping review are 
shown in online supplemental file 1.
Project phase 3: Delphi study
The objectives of our Delphi study were: (A) to obtain 
feedback on the importance of including each candi-
date item in CONSORT- ROUTINE; (B) to improve the 
wording of items considered important; and (C) to elicit 
suggestions for additional items not in the existing list. 
We aimed to engage key stakeholders across different 
sectors and backgrounds. There are not fixed guide-
lines on the sample size of Delphi studies, and the ideal 
number of participants may depend on the complexity 
of the topic, the likely heterogeneity of relevant experi-
ences and viewpoints, and resources available to manage 
the data generated.29–31 Many studies use small groups 
of experts (eg, <20), but we believed that a larger group 
with diverse expertise would best complement the knowl-
edge of the project team. Thus, we sent out an invita-
tion to reporting guideline developers (including those 
involved in previous CONSORT extensions), funders, 
journal editors, patient representatives, trial methodol-
ogists, epidemiologists, meta- research authors, ethicists, 
biostatisticians and clinical triallists who were identified 
by members of the project team. We also encouraged 
recipients of the invitation to forward the invitation to 
other potentially interested stakeholders.
The Delphi surveys were built and hosted using an 
online survey platform in Qualtrics. During registration, 
we gathered demographic and professional background 
characteristics of participants, including geographical 
location, self- identified stakeholder group (eg, clinical 
trials user, clinical triallist and methodologist), employ-
ment sector, years of experience in trials research and 
research experience in trials conducted using cohorts or 
routinely collected data.
Registered participants received a link to access each 
of the three rounds of the Delphi survey. In each round, 
we asked participants to rate their perceptions about the 
importance of each suggested reporting item by ranking 
items based on how essential they are for reporting on a 
1–5 Likert scale (1=not essential; 5=essential). There is 
not consensus on the ideal number of Likert categories 
or groupings for decision- making, but it is common to 
use between 4- point and 7- point scales.30
Responses were categorised as follows:
1–2=low score (item should not be part of CONSORT- 
ROUTINE checklist).
3=moderate (item should be discussed).
4–5=high score (item should be part of CONSORT- 
ROUTINE checklist).
Participants also had the option to select ‘Not my 
expertise’ for items if they believed that they did not have 
the appropriate level of expertise to rate an item. Figure 2 
shows a screenshot of an example proposed modification 
item from the survey:
Items from the CONSORT 2010 statement for which 
modifications were initially not proposed were also 
included in the survey so that participants could provide 
comments or make recommendations for modifications 
to these items. For all items (proposed modifications and 
CONSORT 2010 items), we provided participants with 
the opportunity to give open- ended feedback, using free- 
text boxes provided at the bottom of each survey page 
and at the end of the survey. At the end of the survey, 
participants were asked to provide any additional items 
that they believed would be important for reporting in 
trials conducted using cohorts and routinely collected 
data but that had not been included in the proposed set 
of new and modified items.
We launched round 1 of the survey on 4 February 2019 
with 2 weeks to provide responses. Round 2 was launched 
on 4 March 2019, and round 3 was launched on 1 April 
2019. After each round, the Qualtrics built- in analysis 
software was used to generate a distribution of scores 
and to aggregate group results for each item (mean 
score, maximum and minimum score, SD, variance 
Figure 2 Example of a round 1 Delphi survey item as 
presented in the online survey. CONSORT, Consolidated 
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and percentage ratings of 1–5 ranking for items) and 
summary statistics were circulated among all partici-
pants. Individual responses were not fed back. In addi-
tion, a bar chart with the ratings and counts for each 
item was created. Following each round of the survey, 
the CONSORT- ROUTINE steering committee members 
reviewed the survey results independently and then met 
via teleconference to discuss and analyse the results of 
the survey. During these meetings, decisions were made 
on how to address comments from participants by modi-
fying, adding or combining items. Notes were also made 
on comments that reflected a need for explanation in the 
Explanation & Elaboration companion to the checklist.
We predefined consensus as at least 2/3 of responders 
rating the importance of an item as ‘high’ or ‘very high’. 
Items that reached consensus for inclusion were not 
rated again in the next round. For some items that did 
not reach consensus, the wording of items was revised 
based on participants’ suggestions. Items that did not 
reach consensus were rated again in the next round in 
their original or revised form. Reports summarising the 
Delphi results were circulated after each round including 
summary statistics such as counts, means, SD and vari-
ances for the responses on each item. Reminder emails 
were sent 1 week prior to the deadline and extensions 
were provided if requested for all three rounds in order 
to maximise participation.
Since the Delphi Study was advisory, all items were 
reviewed and vetted again at the in- person consensus 
meeting, and comments provided by participants of the 
Delphi Study were taken into consideration while making 
decisions to include or exclude items.
Project phase 4: in-person consensus meeting and 
development of checklist publication
A 2- day in- person consensus meeting was held on 13–14 
May 2019 in London, UK. The purpose of the meeting 
was to discuss the Delphi results, make decisions on items 
to retain in the final checklist, make any necessary modifi-
cations to items and suggest reporting aspects that should 
be addressed in the Explanation & Elaboration documen-
tation supporting the checklist. The meeting was attended 
by 26 members of the CONSORT- ROUTINE Group.
We used approaches similar to those used in previous 
consensus meetings for other guidelines. Participants were 
provided with the results of the initial long- list generation 
and the Delphi study in advance of the meeting. At the 
meeting, steering committee members first presented the 
background and an update on work done to date, in order 
to facilitate the discussions. Session chairs then separately 
presented items from the preliminary checklist, results of 
the Delphi study and feedback from stakeholders, after 
which the group discussed in an open forum. Decisions 
were made on items to be modified or added based on the 
following criteria: (1) whether they addressed elements 
unique to trials conducted using cohorts or routinely 
collected data versus elements applicable to any trial and 
(2) whether they reflected information that should be 
included in a minimum reporting set of items. Notes were 
taken, and the discussions were audio- recorded to ensure 
that the content was accurately captured.
Following the consensus meeting, refinement of the 
content and wording of the items was continued through 
online group discussions with CONSORT- ROUTINE 
project team members. The initial version of the checklist 
was pilot- tested by circulating it among stakeholders in 
order to assess its usability and to identify any challenges 
that might arise while applying the checklist. Pilot- testing 
the checklist also provided insight into issues that should 
be addressed in detail in the Explanation & Elaboration 
statement.
Project phase 5: publication, dissemination and 
implementation
As with several previous CONSORT extensions, it was 
decided to publish the reporting checklist with a detailed 
Explanation & Elaboration statement in the same docu-
ment.6–9 The Explanation & Elaboration statement is 
intended to provide an in- depth explanation of the scien-
tific rationale for each recommendation, together with 
an example of clear reporting for each item.
In addition to publication of the reporting guideline 
checklist and Explanation & Elaboration material, to 
attempt to maximise uptake, we will undertake additional 
dissemination activities, including presentations and 
workshops at conferences and other venues. We also plan 
to seek endorsement of the guideline by journal editors. 
Research has shown that formal endorsement and adop-
tion of the CONSORT statement by journals is associated 
with improved quality of reporting.2 Studies conducted by 
members of our team have benchmarked pre- extension 
reporting completeness in trials conducted in cohorts, 
registries, EHRs, and administrative databases.32–34 
There were not enough examples of completed cohort- 
embedded trials for benchmarking reporting.
The final CONSORT- ROUTINE checklist (Kwakkenbos 
et al, under review) has been published at: online supple-
mental material.
Patient and public involvement
One of the members of our CONSORT- ROUTINE 
team, MSau, is a patient organisation leader. She has 
been involved in working with researchers to establish 
a cohort of patients living with the rare disease sclero-
derma, which supports RCTs of trials of online rehabili-
tation, self- management and psychological intervention 
programmes.
RESULTS
Stage 2: scoping review and initial long list of potential items
The scoping review sought methods articles and reports 
of trials conducted using cohorts, registries, EHRs or 
administrative databases.
Cohorts
The database search identified 1185 publications, of which 
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37 after full- text review. A total of 86 studies were included 
in the scoping review, including 15 papers on method-
ological considerations of using cohorts for conducting 
RCTs. All trials used the cohort for both identification of 
patients and outcome ascertainment.
Registries
The search identified 234 publications, of which 143 
received full- text review. A total of 106 publications were 
eligible, including 95 trial reports or protocols (both 
identification of patients and outcome ascertainment 
(n=27); identification of patients only (n=28); outcome 
ascertainment only (n=40)) and 11 papers on method-
ological considerations.
Electronic health records
The search identified 2085 citations, of which 548 studies 
were reviewed at the full- text level. A total of 289 eligible 
publications, including 263 trial protocols or reports 
(both identification of patients and outcome ascertain-
ment (n=169); identification of patients only (n=38); 
outcome ascertainment only (n=56)) and 26 articles that 
described methodological considerations.
Administrative databases
The search identified 663 citations, of which 151 full 
texts were reviewed. There were a total of 117 trial 
protocols or reports included (both identification of 
patients and outcome ascertainment (n=57); iden-
tification of patients only (n=1); outcome ascertain-
ment only (n=58)) and one paper on methodological 
considerations.
Delphi study results
Of 125 people invited to take part in the Delphi study, 
115 people registered via an online survey, and 92 (74%) 
provided responses on the items in round 1. Figures 3 
and 4 present the types of stakeholder groups that 
completed round 1 of the Delphi study and the type of 
trials conducted using cohorts or routinely collected 
databases with which they had familiarity. Participants 
belonging to more than one category had the option of 
checking multiple options in the survey.
Round 1
Of the 92 participants who completed the round 1 survey, 
90 provided valid ratings and two provided comments but 
not ratings. Of the 27 items rated in round 1, 14 reached 
consensus to be included in discussions at the consensus 
meeting; the other 13 did not reach consensus and were 
included in round 2. Based on round 1 feedback, a total 
of 11 items were modified for review in round 2, including 
two items that were combined into one. No items were 
excluded from the checklist.
Figure 3 Professional roles reported by participants who completed round 1 of the CONSORT- ROUTINE Delphi study (%). 
Participants could report more than one role. CONSORT- ROUTINE, Consolidated Standards of Reporting Trials Extension for 
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Round 2
Of the 92 participants who completed round 1, 77 (84%) 
completed the round 2 survey. Of the 13 items rated, 2 
reached consensus for inclusion in consensus meeting 
discussions, and 11 did not reach consensus in round 2. 
Based on round 2 feedback, eight items were modified 
prior to round 3.
Round 3
Of the 77 people who completed round 2, 62 (81%) 
completed round 3. Of the 11 items in round 3, five items 
reached consensus in round 3. The remaining six items 
did not reach consensus after the three rounds.
There were several new items suggested via the Delphi 
process but not added to the potential item list. The main 
reasons why some items were suggested but not incorpo-
rated were:
1. The suggestion was encapsulated in CONSORT 2010 
items, was already captured by proposed new or mod-
ified items or could be captured by further modifying 
new or modified items.
2. The suggestion was not specific to trials conducted 
using cohorts and routinely collected data and, thus, 
was recommending a change to the CONSORT 2010 
checklist, which was not the task of the CONSORT- 
ROUTINE group.
Summary results of the three rounds can be accessed at: 
https:// osf. io/ 4zh6f/
In-person consensus meeting
Table 1 summarises the CONSORT- ROUTINE group’s 
discussions and advisory decisions for each of the items 
that was discussed during the in- person meeting. If there 
were differing opinions on the inclusion or exclusion of 
items and consensus could not be reached, voting was 
implemented by the session chair, with an 80% threshold 
for inclusion in the checklist as part of the minimal set 
of recommended reporting items. The key recommenda-
tions that emerged were as follows:
 ► Proposed modification to CONSORT 2010 items: it 
was recommended to retain proposed modifications 
to seven CONSORT 2010 items. These modifica-
tions pertained to differences in mechanisms used 
to conduct trials using cohorts or routinely collected 
databases. As in previous CONSORT extensions, some 
of the recommended changes end with ‘if applicable’ 
to show that some information which authors are 
being asked to report might not be relevant or appli-
cable for their particular RCT or the particular type of 
data that was used in the RCT.
 ► Proposed additional items: consensus was reached 
to include six additional items and to add a new 
subheading, ‘Cohort or routinely collected database’, 
to the checklist.
A recurrent discussion point was the need to minimise 
adding new items to the abstract unless they are essential 
due to word limits imposed by journals. A suggestion was 
made to expand the explanatory text of the Explanation 
& Elaboration document for nine unchanged CONSORT 
2010 items to clarify additional requirements for reporting 
aspects of the trial without modifying the item: item 1a 
(identification as a randomised trial in the title), item 4b 
(settings and location where the data were collected), item 5 
(intervention), item 13b (losses and exclusions after rando-
misation), item 14a (dates of recruitment/follow- up), item 
15 (baseline data), item 20 (limitations), item 21 (gener-
alisability) and item 24 (study protocol). For the abstract, 
there was an agreement to include an additional item to 
the abstract for naming the cohort or routinely collected 
database (item 1c). This item was later merged with item 
1b from the CONSORT 2010 checklist after discussion with 
the project team (table 1). Thus, the final extension check-
list included eight modified items and five new items.23
CONSORT-ROUTINE pilot test
The preliminary version of the checklist was pilot- tested by 
17 people who had been previously involved in conducting 
trials using cohorts and routinely collected data. Based on 
feedback received from the pilot test, there were minor modi-
fications made to the wording of two items for clarity (item 1b 
and item 9) in the final checklist.23
Figure 4 Participants of round 1 of the CONSORT- ROUTINE Delphi study by type of cohort or routinely collected database 
with which they had familiarity (%). Participants could report more than one. CONSORT- ROUTINE, Consolidated Standards of 





































































































































ext. item CONSORT 2010 item





Summary of the discussion, decisions 
and suggestions made during the 
CONSORT- ROUTINE in- person 
consensus meeting




  1a 1a Identification as a randomised 
trial in the title.
Identification as a randomised trial 
in the title, including that it was a 
trial conducted using a cohort or 
routinely collected source of data 
(modified).
Not reached. Discussed the need for a modification to 
the original item. It was noted that multiple 
databases or types of databases could 
be used to conduct a trial and stating all 
would not be feasible as journals might 
have title length restrictions.
Decision: do not include the modification 
and retain the CONSORT 2010 item; 
expand the E&E text for clarification.
Identification as a randomised trial in the 
title.
1b 1b Structured summary of trial 
design, methods, results 
and conclusions (for specific 
guidance see CONSORT for 
abstracts).
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Note: additional item 1c was later merged 
with this item (see further).
Structured summary of trial design, 
methods, results and conclusions (for 
specific guidance, see CONSORT for 
abstracts). Specify that a cohort or 
routinely collected data were used to 
conduct the trial and, if applicable, 
provide the name of the cohort or 
routinely collected database(s).
  The source(s) of data used 
to conduct the trial should 




Noted the importance of stating the cohort 
or routinely collected database(s) used to 
conduct the trial in the abstract, if not in 
the title.
Decision: include the suggested new item 
with revisions.
Note: the item was later merged with item 
1b from CONSORT 2010.
  
  If linkage between multiple 
sources of data was conducted for 
the study, this should be clearly 
stated in the abstract (additional).
Not reached. Mixed views on the necessity of reporting 
the suggested new item in the abstract. 
Agreed that linkage is important to 
report in the body of the paper but not 
necessarily the abstract.
Decision: do not include the suggested 
new item.
  
  The proportion of participants 
offered and the proportion that 
accepted the intervention should 
be reported (for trials conducted 




Mixed views on the necessity of reporting 
the suggested new item in the abstract. 
Agreement that the information is 
important to report but not essential 
for the abstract due to word count 
restrictions. In addition, this applies to 
one trial design used in cohorts but not 
all cohort trials and not trials using other 
types of data. The item was merged with 
CONSORT 2010 item 13a (14a in the 
final extension checklist) pertaining to 
participant flow.
Decision: do not include the suggested 
new item in the abstract but include in 
item 14a in the final extension checklist.
  
Continued

























ext. item CONSORT 2010 item





Summary of the discussion, decisions 
and suggestions made during the 
CONSORT- ROUTINE in- person 
consensus meeting





2a 2a Scientific background and 
explanation of rationale.
    Discussed the importance of reporting 
the rationale for conducting the trial using 
a cohort or routinely collected database 
but decided against modifying original 
CONSORT 2010 item.
Decision: retain the CONSORT 2010 item.
Scientific background and explanation of 
rationale.
2b 2b Specific objectives or hypotheses     No suggested modification.
Decision: retain the CONSORT 2010 item.
Specific objectives or hypotheses.
Methods
Trial design 3a 3a Description of trial design (such 
as parallel, factorial) including 
allocation ratio.
Description of trial design (such 
as parallel and factorial) including 
allocation ratio, the source(s) of 
data used to conduct the trial 
(such as cohort and registry) and 
how the data are used within 
the trial (such as identification 
of eligible trial participants, trial 
outcomes) (modified).
  Noted that key elements of the study 
design and cohort or database(s) used 
for the trial should be stated early in the 
methods section, as well as the extent to 
which the database was used in the trial.
Decision: include the modified item.
Description of trial design (such as 
parallel and factorial) including allocation 
ratio, that a cohort or routinely collected 
database(s) used to conduct the trial 
(such as electronic health record and 
registry) and how the data were used 
within the trial (such as identification 
of eligible trial participants and trial 
outcomes).
3b 3b Important changes to methods 
after trial commencement 
(such as eligibility criteria), with 
reasons.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Important changes to methods after 








ROUTINE-1   Description of the source(s) of 
data used to conduct the trial, 
including the setting, locations, 
relevant dates, periods of 




Agreed on the importance of reporting 
the item.
Decision: include the suggested new item.
Name, if applicable, and description 
of the cohort or routinely collected 
database(s) used to conduct the trial, 
including information on the setting (such 
as primary care), locations and dates 
(such as periods of recruitment, follow- up 
and data collection).
  Describe indicators of the quality 
of the source(s) of data used 
to conduct the trial including 
what types of quality checks 
have been performed and the 




Mixed views on the necessity of the 
suggested new item. There were 
concerns that ‘quality’ is vague and the 
term ‘accuracy and completeness’ may 
better clarify the intent of the item. It 
was acknowledged that the accuracy 
and completeness of the cohort or 
database is important to report while (1) 
selecting participants and (2) ascertaining 
outcomes.
Decision: do not include the suggested 
new item as a standalone item. The item 
was merged with extension items 5a and 
7b (pertaining to participant selection and 
































ext. item CONSORT 2010 item





Summary of the discussion, decisions 
and suggestions made during the 
CONSORT- ROUTINE in- person 
consensus meeting
Final checklist item to be included in 
CONSORT- ROUTINE
  Describe modifications to the data 
collected in the source(s) of data 
used to conduct the trial, such as 




Agreed that the suggested item is not 
necessarily unique to trials conducted 
using cohorts and routinely collected data.
Decision: do not include the suggested 
new item; expand the E&E text for 
clarification.
  
  Describe additional sources of 




Mixed views on the necessity of the 
suggested new item as it is not unique 
to trials conducted using cohorts and 
routinely collected data.
Decision: do not include the suggested 
new item; expand the E&E text for 
clarification.
  
ROUTINE-2   Give the eligibility criteria, the 
sources and methods of selection 
of participants, and methods of 
follow- up (for trials conducted 




Discussed the importance of reporting the 
eligibility criteria for inclusion in the cohort 
or routinely collected database(s), but 
there was concern that elements related 
to follow- up are not specific to trials 
conducted using cohorts and routinely 
collected data.
Decision: include the suggested new item 
with revisions; expand the E&E text for 
clarification of other aspects.
Eligibility criteria for participants in the 
cohort or routinely collected database(s).
ROUTINE-3   Detail any use of record linkage 
across sources of data, the 
methods of linkage and methods 




Suggestion to integrate wording from 
RECORD checklist for clarity.
Decision: include the suggested new item 
adapted from RECORD.
State whether the study included person- 
level, institutional- level or other data 
linkage across two or more databases 
and, if so, linkage techniques and 
methods used to evaluate completeness 
and accuracy of linkage.
  Describe if (and how) participants 
were informed about the potential 
use of their data in randomised 
trials (additional).
Not reached Mixed views on the necessity of the 
item as some believed that ethics 
considerations are beyond the scope of 
CONSORT, and ethics does not appear 
in CONSORT 2010. The group agreed 
to include the item as consent is an 
important issue with unique aspects 
in these trials, but that this should be 
presented as part of trial participants 
section.
Decision: include the suggested new item 
with revisions and move to section ‘Trial 






























ext. item CONSORT 2010 item





Summary of the discussion, decisions 
and suggestions made during the 
CONSORT- ROUTINE in- person 
consensus meeting






4a 4a Eligibility criteria for participants. Eligibility criteria for trial 
participants (modified).
  Agreed to merge with suggested new item 
(see next row).
Decision: merge with suggested new item, 
‘Provide details of how eligible clusters/
participants were identified from the 
source(s) of data used to conduct the trial’.
Eligibility criteria for trial participants, 
including information on how to access 
the list of codes and algorithms used to 
identify eligible participants, information 
on accuracy and completeness of 
data used to ascertain eligibility and 
methods used to validate accuracy 
and completeness (eg, monitoring, 
adjudication), if applicable.
  Provide details of how eligible 
clusters/participants were 
identified from the source(s) of 




Suggested merging with CONSORT 2010 
item 4a (5a in final checklist) and address 
accuracy and completeness of data.
Decision: merge the suggested new item 
with CONOSRT 2010 item 4a (5a in the 
final checklist).
  
4b 4b Settings and locations where the 
data were collected.
Settings and locations where 




The word ‘trial’ was dropped as the header 
‘Trial participants’ clarifies the intent of 
the item.
Decision: retain the CONSORT 2010 item; 
expand the E&E text for clarification.
Settings and locations where the data 
were collected.
ROUTINE-4   Details of information provided 
to participants from the source(s) 
of data who are selected for 
recruitment or inclusion in the 
trial, including any differences in 
information provided across trial 
arms (additional).
Not reached. Extended discussions on the importance 
of the item as it might only be applicable 
to the controlled multiple RCT design. 
Agreement to formulate as a general item 
on consent as item 5 c.
Decision: do not include the suggested 
new item. The consent item was simplified 
and moved to this section. Expand the 
E&E text for clarification of consent issues.
Describe whether and how consent was 
obtained.
Interventions 5 5 The interventions for each 
group with sufficient details to 
allow replication, including how 
and when they were actually 
administered.
    No suggested modification.
Decision: retain the CONSORT 2010 item; 
expand the E&E text for clarification.
The interventions for each group with 
sufficient details to allow replication, 
including how and when they were 
actually administered.
    Describe how the source(s) of 
data was used to implement the 
intervention, if applicable (eg, for 




Debated the necessity of the new item as 
it is only applicable to trials conducted 
using electronic health records that may 
be used as intervention tools.
Decision: do not include the suggested 
new item; expand the E&E text for 
clarification.
  
Outcomes 6a 6a Completely defined prespecified 
primary and secondary outcome 
measures, including how and 
when they were assessed.
    Suggestion to merge with proposed new 
item, ‘Provide source(s) of data for each 
outcome’ (see below).
Decision: item merged with suggested 
new item and included in the final 
checklist.
Completely defined prespecified primary 
and secondary outcome measures, 
including how and when they were 
ascertained and the cohort or routinely 































ext. item CONSORT 2010 item





Summary of the discussion, decisions 
and suggestions made during the 
CONSORT- ROUTINE in- person 
consensus meeting
Final checklist item to be included in 
CONSORT- ROUTINE




Suggestion to merge with CONSORT 2010 
item 6a.
Decision: item merged with CONSORT 
2010 item 6a (7a in the final checklist).
  
ROUTINE-5   Provide a list of codes and 
algorithms used to define (and/
or derive) the outcomes as 
online supplemental information, 
including validation, if applicable 
(additional).
Not reached. Acknowledged the importance of reporting 
the list of codes and algorithms for 
ascertaining outcomes along with the 
accuracy and completeness of data and 
validation.
Decision: include the suggested new item 
with revisions.
Information on how to access the list of 
codes and algorithms used to define or 
derive the outcomes from the cohort or 
routinely collected database(s) used to 
conduct the trial, information on accuracy 
and completeness of outcome variables 
and methods used to validate accuracy 
and completeness (eg, monitoring, 
adjudication), if applicable.
  Detail any adjudication or external 
validation of data items from the 
source(s) of data used to conduct 
the trial, if applicable (additional).
Reached for 
inclusion.
Acknowledged the importance of 
reporting the item. There was agreement 
that validation should be reported while 
selecting participants and ascertaining 
outcomes and included as part of items 5a 
and 7b of extension checklist.
Decision: address elements of proposed 
item as part of items 5a and 7b in the final 
checklist.
  
6b 6b Any changes to trial outcomes 
after the trial commenced, with 
reasons.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Any changes to trial outcomes after the 
trial commenced, with reasons.
Sample size 7a 7a How sample size was 
determined.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
  How sample size was determined.
7b 7b When applicable, explanation 
of any interim analyses and 
stopping guidelines.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
When applicable, explanation of any 
interim analyses and stopping guidelines.
Randomisation
  Sequence 
generation
8a 8a Method used to generate the 
random allocation sequence.
    No suggested modification.
Decision: retain the CONSORT 2010 item; 
expand the E&E text for clarification.
  Method used to generate the random 
allocation sequence.
8b 8b Type of randomisation; details of 
any restriction (such as blocking 
and block size).
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Type of randomisation; details of any 
restriction (such as blocking and block 
size).
  Allocation 
concealment 
mechanism
9 9 Mechanism used to implement 
the random allocation sequence 
(such as sequentially numbered 
containers), describing any steps 
taken to conceal the sequence 
until interventions were assigned.
Mechanism used to implement 
the random allocation sequence, 
describing any steps taken 
to conceal the sequence until 
interventions were assigned, 
such as using automated random 
sequence generation concealed 
within source(s) of data (modified).
Reached for 
inclusion.
Discussion to clarify wording of the item.
Decision: include the modified item with 
revisions.
Mechanism used to implement the 
random allocation sequence (such as 
embedding an automated randomiser 
within the cohort or routinely collected 
database(s)), describing any steps 






























ext. item CONSORT 2010 item





Summary of the discussion, decisions 
and suggestions made during the 
CONSORT- ROUTINE in- person 
consensus meeting
Final checklist item to be included in 
CONSORT- ROUTINE
Implementation 10 10 Who generated the random 
allocation sequence, who 
enrolled participants and 
who assigned participants to 
interventions.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Who generated the random allocation 
sequence, who enrolled participants 
and who assigned participants to 
interventions.
Blinding 11a 11a If done, who was blinded after 
assignment to interventions (eg, 
participants, care providers, 
those assessing outcomes) and 
how.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
If done, who was blinded after assignment 
to interventions (eg, participants, care 
providers, those assessing outcomes) 
and how.
11b 11b If relevant, description of the 
similarity of interventions.
    No suggested modification.
Decision: retain the CONSORT 2010 item.




12a 12a Statistical methods used to 
compare groups for primary and 
secondary outcomes.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Statistical methods used to compare 
groups for primary and secondary 
outcomes.
12b 12b Methods for additional analyses, 
such as subgroup analyses and 
adjusted analyses.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Methods for additional analyses, such 




flow (a diagram 
is strongly 
recommended)
13a 13a For each group, the numbers of 
participants who were randomly 
assigned, received intended 
treatment and were analysed for 
the primary outcome.
Describe in detail the numbers 
of clusters/participants in the 
source(s) of data used to conduct 
the trial, number screened for 
eligibility, randomly assigned, 
offered and accepted interventions 
(eg, cohort multiple RCTs), 
received intended treatment and 




Suggestion to form a committee to draft 
example flow diagram and oversee the 
E&E.
Decision: include the modified item; 
committee to oversee the E&E 
development.
For each group, the number of 
participants in the cohort or routinely 
collected database(s) used to conduct 
the trial and the numbers screened for 
eligibility, randomly assigned, offered 
and accepted interventions (eg, cohort 
multiple RCTs), received intended 
treatment and analysed for the primary 
outcome.
  Describe any linkage of multiple 
sources of data, including the 




Debated the necessity of the item as 
a stand- alone item as linkage was 
addressed in item 4c. Suggested to 
include the number of clusters/participants 
successfully linked as part of the flow 
diagram.
Decision: do not include the suggested 
new item; expand the E&E text for 
clarification.
  
13b 13b For each group, losses and 
exclusions after randomisation, 
together with reasons.
    No suggested modification. Discussed 
that the item should be tied to data 
accuracy and completeness, and linkage.
Decision: retain the CONSORT 2010 item; 
expand the E&E text for clarification.
For each group, losses and exclusions 































ext. item CONSORT 2010 item





Summary of the discussion, decisions 
and suggestions made during the 
CONSORT- ROUTINE in- person 
consensus meeting
Final checklist item to be included in 
CONSORT- ROUTINE
Recruitment 14a 14a Dates defining the periods of 
recruitment and follow- up.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Dates defining the periods of recruitment 
and follow- up.
14b 14b Why the trial ended or was 
stopped.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Why the trial ended or was stopped.
Baseline data 15 15 A table showing baseline 
demographic and clinical 
characteristics for each group.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
A table showing baseline demographic 
and clinical characteristics for each 
group.
  A table showing baseline 
demographic and clinical 
characteristics for eligible 
participants who participated in 




Agreement to not include the suggested 
new item as a stand- alone item. The 
information should be reported if possible, 
but not necessary, and implications should 
be addressed as part of ‘Generalisability’ 
(item 21).





16 16 For each group, number of 
participants (denominator) 
included in each analysis and 
whether the analysis was by 
original assigned groups.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
For each group, number of participants 
(denominator) included in each analysis 




17a 17a For each primary and secondary 
outcome, results for each group, 
and the estimated effect size and 
its precision (such as 95% CI).
    No suggested modification.
Decision: retain the CONSORT 2010 item.
For each primary and secondary 
outcome, results for each group, and the 
estimated effect size and its precision 
(such as 95% CI).
  17b 17b For binary outcomes, 
presentation of both absolute 
and relative effect sizes is 
recommended.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
For binary outcomes, presentation of 




18 18 Results of any other analyses 
performed, including subgroup 
analyses and adjusted analyses, 
distinguishing prespecified from 
exploratory.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Results of any other analyses performed, 
including subgroup analyses and adjusted 
analyses, distinguishing prespecified from 
exploratory.
  If outcomes for eligible patients in 
the existing source(s) of data who 
were not included in the trial are 
known, they should be reported 
(additional).
Not reached. Agreement to not include the suggested 
new item as a stand- alone item. The 
information should be reported if possible, 
but not necessary, and implications should 
be addressed as part of ‘Generalisability’.
Decision: do not include the suggested 
new item; expand the E&E text for 
clarification in the ‘Generalisability’ 
section.
  
Harms 19 19 All important harms or 
unintended effects in each 
group (for specific guidance see 
CONSORT for harms).
    No suggested modification.
Decision: retain the CONSORT 2010 item.
All important harms or unintended effects 






























ext. item CONSORT 2010 item





Summary of the discussion, decisions 
and suggestions made during the 
CONSORT- ROUTINE in- person 
consensus meeting
Final checklist item to be included in 
CONSORT- ROUTINE
Discussion
Limitations 20 20 Trial limitations, addressing 
sources of potential bias, 
imprecision, and, if relevant, 
multiplicity of analyses.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Trial limitations, addressing sources 
of potential bias, imprecision, and, if 
relevant, multiplicity of analyses.
    Discuss the implications of using 
data that were not created or 




Discussed that using routinely collected 
data is not necessarily a limitation, and the 
content of this item should be addressed 
in the ‘Interpretation’ section.
Decision: do not include the suggested 
new item; merge with CONSORT 2010 
item 22 (23 in the final checklist); expand 
the E&E text for clarification in the 
‘Generalisability’ section.
  
Generalisability 21 21 Generalisability (external validity 
and applicability) of the trial 
findings.
    No suggested modification. Agreement to 
elaborate on the representativeness of the 
cohort or routinely collected database(s) 
used for the trial, including issues related 
to characteristics of eligible cohort or 
database participants who do not agree to 
participate in trial.
Decision: retain the CONSORT 2010 item; 
expand the E&E text for clarification.
Generalisability (external validity and 
applicability) of the trial findings.
Interpretation 22 22 Interpretation consistent with 
results, balancing benefits and 
harms and considering other 
relevant evidence.
    Item merged with the proposed new item 
‘Discuss the implications of using data 
that were not created or collected to 
answer the specific research question(s)’.
Decision: include the modified item.
Interpretation consistent with results, 
balancing benefits and harms and 
considering other relevant evidence, 
including the implications of using data 
that were not collected to answer the trial 
research questions.
Other information
Registration 23 23 Registration number and name of 
trial registry.
    No suggested modification.
Decision: retain the CONSORT 2010 item.
Registration number and name of trial 
registry.
Protocol 24 24 Where the full trial protocol can 
be accessed, if available.
    No suggested modification.
Decision: retain the CONSORT 2010 item; 
expand the E&E text for clarification.
Where the full trial protocol can be 
accessed, if available.
Funding 25 25 Sources of funding and other 
support (such as supply of 
drugs), role of funders.
Sources of funding and other 
support for the trial and the 




Suggested minor revision to the item.
Decision: include the modified item with 
revision.
Sources of funding and other support for 
both the trial and the cohort or routinely 
collected database(s), role of funders
CONSORT, Consolidated Standards of Reporting Trials; E&E, Explanation & Elaboration; RCT, randomised controlled trial; ROUTINE, Extension for Trials Conducted Using Cohorts and Routinely Collected Data.
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DISCUSSION
We have developed a consensus- driven extension to the 
CONSORT 2010 Statement for RCTs conducted using 
cohorts and routinely collected data (Kwakkenbos et al).24 
CONSORT- ROUTINE contains minimum reporting 
requirements with appropriate flexibility as described in the 
Explanation & Elaboration part of our checklist document. 
This article described how we reached the final checklist and 
Explanation & Elaboration text and provides information 
on the decision- making process. We anticipate this paper 
will help others who may learn from our experiences and 
may apply this to the development of future guidelines or 
extensions.
There were several important strengths to our approach. 
A consensus- driven Delphi methodology, which is recom-
mended when developing healthcare reporting guide-
lines by the EQUATOR network, was used to develop 
the extension.23 We engaged with key stakeholders in 
trials research and potential end- users of the resultant 
CONSORT- ROUTINE reporting guideline throughout 
the development process. The process involved partici-
pants from a wide range of scientific disciplines and with 
diverse experience in conducting trials using different 
cohorts and routinely collected databases. As with other 
CONSORT- related guidelines, the inclusion of CONSORT 
Group members (IB, DM and PR) was intended to ensure 
consistency in the use of recommended methods in the 
development, dissemination and implementation of 
the extension. We recorded high response rates of 74% 
(92 respondents), 84% (77 respondents) and 81% (62 
respondents) in Delphi rounds 1, 2 and 3, respectively. 
In addition, the number of registered participants and 
responders is larger than in most Delphi surveys used to 
develop healthcare reporting guidelines.8 35 36 Finally, we 
achieved a high degree of consensus that was consistent 
across Delphi survey rounds for the majority of the items.
There are also limitations to consider. One is that most 
participants were academic researchers with primary 
roles in trials research, and despite our broad engage-
ment efforts, the number of participants from some stake-
holder groups was small. One patient was included as a 
member of the reporting guideline development team, 
but no patients participated in the Delphi exercise. It is 
possible that perceptions about the importance of items 
might have differed across different stakeholder groups 
that might have favoured the inclusion or exclusion of 
certain items. Nonetheless, our project group included 
people from diverse backgrounds with expertise in using 
different types of data sources, who oversaw the devel-
opment process to ensure that the checklist was equally 
applicable to, and representative of, all four types of 
data sources. A second is that our scoping review was 
not designed to capture each and every trial conducted 
using routinely collected data. This was in part because 
of the lack of accepted specific Medical Subject Head-
ings terms to identify these studies, or any research 
using routinely collected data, and the limited number 
of completed trials and methodological articles on these 
trial designs. For our purposes, it was not necessary to 
capture all trials that had been conducted using cohorts 
or routinely collected data, and we believe that we were 
able to capture a significant number of important trial 
reports and methodology papers that served as a basis 
for the development of our extension. A third is that the 
CONSORT- ROUTINE group predominantly consisted of 
members from high- income countries, which might have 
led to decreased applicability of the checklist for trials 
conducted in other settings. Finally, as with all reporting 
guidelines, ours will require re- evaluation and revisions 
over time to ensure that it is kept up to date with evolving 
research and knowledge on these trail designs.
CONCLUSION
CONSORT- ROUTINE has now been developed and can be 
used to support comprehensive reporting of RCTs conducted 
using cohorts or routinely collected data. The extension 
statement contains minimum requirements of reporting that 
we encourage researchers to report. A baseline assessment of 
the completeness and reporting of these trial designs is being 
conducted, and the impact of the extension will be assessed 
in the coming years. While we anticipate that CONSORT- 
ROUTINE may need to be updated with the evolution of 
research methods, we hope the guideline will improve the 
reporting of RCTs conducted using cohorts and routinely 
collected data, enhance their interpretability and credibility 
of their results, improve their reproducibility, indirectly facil-
itate their robust design and conduct and lead to improved 
patient care.
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